Sarrif A M, Durant J R
Cancer. 1981 Sep 1;48(5):1215-20. doi: 10.1002/1097-0142(19810901)48:5<1215::aid-cncr2820480527>3.0.co;2-3.
A small number of primary metastatic breast carcinomas are estrogen-receptor-negative and progesterone-receptor-positive (ER-, PGR+) under the normal ligand-binding assay or sucrose density gradient conditions. Among more than 500 tumors analyzed in this laboratory over a year and a half, 28 cases fit this category, 18 of which were patients 51 years of age or younger (Group A) and 7 were patients over the age of 56 (Group B), The ages of three patients were unknown (Group C). By treatment of each of those tumor cytosols with dextran-coated charcoal before the assay was done, 13 of group A became positive (ER range 10-87 fmol/mg protein); 1 was borderline (ER 3-9 fmol/mg protein); 1 became positive only on sucrose gradient determination, and 2 remained negative. In comparison, two patients in group B shifted from borderline ER to ER+ and only one ER- became ER+ at 10 fmol/mg protein. The data provide additional rationale for determining both ER and PGR in all patients, and have obvious implications for the need of standard methods of determining ER and PGR in the prognosis of women with breast cancer.
在正常配体结合分析或蔗糖密度梯度条件下，少数原发性转移性乳腺癌雌激素受体阴性而孕激素受体阳性（ER-，PGR+）。在本实验室一年半时间内分析的500多例肿瘤中，有28例符合这一类别，其中18例为51岁及以下患者（A组），7例为56岁以上患者（B组），3例患者年龄未知（C组）。在进行分析之前，用葡聚糖包被活性炭处理这些肿瘤细胞溶胶，A组中有13例变为阳性（ER范围为10 - 87 fmol/mg蛋白质）；1例处于临界值（ER为3 - 9 fmol/mg蛋白质）；1例仅在蔗糖梯度测定时变为阳性，2例仍为阴性。相比之下，B组中有2例从临界ER转变为ER+，只有1例ER-在10 fmol/mg蛋白质时变为ER+。这些数据为在所有患者中同时测定ER和PGR提供了更多依据，并且对于乳腺癌女性患者预后中ER和PGR测定标准方法的必要性具有明显的意义。
